Tobradex ST, a treatment for inflammatory ocular conditions, has been launched in the United States, Eyevance Pharmaceuticals announced in a press release.
Tobradex ST (tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05%) includes XanGen, the company’s unique suspension technology formulated with xanthan gum designed to stabilize the combination and allow greater ocular surface retention, the release said.
“We are introducing Tobradex ST to eye care professionals because it holds immense potential for millions of patients suffering from acute blepharitis, meibomian gland
Uncategorized